Related Experiment Video
Updated: May 18, 2026

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Calcium dobesilate may improve hemorheology in patients undergoing coronary artery bypass grafting
Kazim Besirli1, Birsen Aydemir, Caner Arslan
1Cardiovascular Surgery Department, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey. birsenay2001@yahoo.com
Insights
Calcium dobesilate improved erythrocyte flexibility in patients after myocardial revascularization. However, it did not significantly alter blood viscosity, oxidative stress markers, or clinical outcomes like CCS class.
Area of Science:
- Cardiology
- Pharmacology
- Hemodynamics
Background:
- Calcium dobesilate is an angioprotective agent with antioxidant properties.
- It enhances endothelial-derived vasodilator secretion.
- Its effects in the postoperative period following myocardial revascularization remain under-investigated.
Purpose of the Study:
- To evaluate the impact of calcium dobesilate on hemorheological parameters.
- To assess changes in oxidant and antioxidant markers (reduced glutathione and malondialdehyde).
- To determine effects in patients undergoing myocardial revascularization post-surgery.
Main Methods:
- A study involving 134 patients undergoing coronary heart disease surgery.
- Measurement of hemorheological, oxidant, and antioxidant parameters pre- and post-treatment.
- A treatment group received 500 mg calcium dobesilate twice daily for three months; a control group did not.
Main Results:
- Significant improvement in erythrocyte deformability index observed post-calcium dobesilate administration.
- No significant changes noted in blood viscosity, glutathione (GSH), or malondialdehyde (MDA) levels.
- Similar improvement in Canadian Cardiovascular Society (CCS) class observed in both treatment and control groups.
Conclusions:
- Calcium dobesilate significantly enhances erythrocyte flexibility.
- The drug did not demonstrate significant effects on blood viscosity or key oxidative stress markers.
- Clinical improvement in CCS class was independent of calcium dobesilate treatment in this cohort.
Background:
Calcium dobesilate is an angioprotective agent that has positive effects on hemorheological parameters. It is an antioxidant that increases endothelial-derived vasodilator substance secretion, there are none that analyze its effects during the postoperative period of patients undergoing myocardial revascularization.
Objective:
We aimed to determine the effects of calcium dobesilate on hemorheological parameters, such as reduced glutathione and malondialdehyde in patients with ischemic heart disease undergoing myocardial revascularization in the postoperative period.
Methods:
One hundred and thirty-four patients operated for coronary heart disease were included in this study. Hemorheological, oxidant and antioxidant parameters were measured two days after surgery and after a period of treatment with calcium dobesilate. Then, 500 mg of calcium dobesilate was given twice a day to one group of 68 patients for three months. The control group was composed of 66 patients who did not receive this medication.
Results:
The increase in the erythrocyte deformability index was found to be significant compared with both the pretreatment values and with the 1st and 2nd values of the control group after calcium dobesilate administration, whereas there were no significant changes in blood viscosity, glutathione (GSH) or malondialdehyde (MDA) values after the calcium dobesilate administration. The same improvement in the CCS class was observed in patients regardless of they received the calcium dobesilate treatment.
Conclusion:
In the present investigation, the same improvement in the CCS class was observed in patients regardless of they received the calcium dobesilate treatment. Improvements with calcium dobesilate were statistically significant only in the increase in erythrocyte flexibility.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Acute Coronary Syndrome IV: Interprofessional Care
